e-therapeutics plc (LON:ETX – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 10.26 ($0.14) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares traded.
e-therapeutics Trading Down 6.7 %
The firm has a market capitalization of £52.59 million, a price-to-earnings ratio of -450.00 and a beta of 0.46. The company has a quick ratio of 20.13, a current ratio of 22.20 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is GBX 9 and its 200 day moving average is GBX 10.26.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Read More
- Five stocks we like better than e-therapeutics
- Stock Splits, Do They Really Impact Investors?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What is the Nikkei 225 index?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
